| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | dinaciclib | CTRPv2 | pan-cancer | AAC | 0.0053 | 0.9 |
| mRNA | JNK-9L | GDSC1000 | pan-cancer | AAC | 0.0038 | 0.9 |
| mRNA | AS605240 | GDSC1000 | pan-cancer | AAC | 0.0035 | 0.9 |
| mRNA | BRD-K11533227 | CTRPv2 | pan-cancer | AAC | 0.004 | 0.9 |
| mRNA | Erlotinib | UHNBreast | pan-cancer | AAC | -0.032 | 0.9 |
| mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | -0.0036 | 0.9 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0038 | 0.9 |
| mRNA | ML210 | CTRPv2 | pan-cancer | AAC | 0.0034 | 0.9 |
| mRNA | BRD-K37390332 | CTRPv2 | pan-cancer | AAC | 0.004 | 0.9 |
| mRNA | OSU-03012 | GDSC1000 | pan-cancer | AAC | -0.0034 | 0.9 |